Low-dose NOAC Versus GDMT After LAAO

Inclusion Criteria: 1. Non-valvular atrial fibrillation (NVAF) patients with successful left atrial appendage occlusion (LAAO) 2. Eligible for guideline-directed anti-thrombotic therapy 3. Able to understand and provide informed consent and comply with all study medications Exclusion Criteria: 1. Under the age of 18 2. Unable to give informed consent or currently participating in another trial and not yet at its primary endpoint 3. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice) 4. Concurrent medical condition with a life expectancy of less than two years 5. Haemodynamical unstable 6. Known contraindication to medications such as heparin, antiplatelet or anticoagulation drugs, or contrast 7. Peridevice leak \> 5mm as assessed immediately after LAAO or any other procedure-related complications 8. Comorbidities other than atrial fibrillation that required long term use of anticoagulation (such as implanted mechanical valve) 9. Percutaneous coronary intervention (PCI) within 1 year. 10. The patient had or is planning to have any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to or 60 days after the WATCHMAN device implant (e.g., PCI, cardioversion, cardiac surgery) 11. Ongoing overt bleeding 12. Previous stroke/TIA within 30 days of enrolment 13. Symptomatic carotid artery disease 14. Severe renal insufficiency (CrCl≤30ml/min/1.73m2)